Action 3692 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Hansoh Pharmaceutical Group Company Limited

Actions

3692

KYG549581067

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:34 17/07/2024 		Varia. 5j. Varia. 1 janv.
17,24 HKD +4,48 % Graphique intraday de Hansoh Pharmaceutical Group Company Limited +8,02 % +9,39 %
14/06 Hansoh Pharmaceutical réduit le prix de conversion des obligations convertibles MT
30/04 Hausse de 27% des bénéfices de Hansoh Pharmaceutical pour 2023 MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference
AQ
Hansoh Pharmaceutical Group Co., Ltd. - The 24th China Patent Awards Ceremony was held, and Hansoh Pharma's Ametinib patent was awarded the China Patent Gold Award
AQ
Hansoh Pharmaceutical's Saint Relais is the first batch to be shipped nationwide, bringing a safe and long-lasting new option to CKD patients with renal anemia
AQ
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
AQ
KiOmed Pharma and Hansoh Pharma Announce License Agreement for KioMedinevsone in China's Mainland, Macau and Taiwan
AQ
Hansoh Pharmaceutical : FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021
PU
Hansoh Pharmaceutical : Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China
AQ
SCYNEXIS : Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
AQ
SCYNEXIS : Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
AQ
Hansoh Pharmaceutical : Accelerate Benefits for Hepatitis B Patients! Hansoh Pharma's New Class 1 Drug Hengmu (Tenofovir Amibufenamide Tablets) Prescribed for the First Time in China
AQ
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF AMEILE IN FIRST LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FDA TENTATIVE APPROVAL OF "BORTEZOMIB FOR INJECTION"
PU
Hansoh Pharmaceutical : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 3, 2021
PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "LENALIDOMIDE CAPSULE"
PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "EMPAGLIFLOZIN TABLETS"
PU
Hansoh Pharmaceutical : INSIDE INFORMATION - LICENSE AGREEMENT WITH EQRX
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 3692
  4. Actualités Hansoh Pharmaceutical Group Company Limited
  5. Communiqués